| Outcome Measures: |
Primary: Difference in change in body weight of the intervention groups, Between baseline and week 32, or end of study | Secondary: Change in fat mass, Between baseline and week 32|Change in lean mass, Between baseline and week 32|Change in insulin sensitivity, Between week 0 and week 32|Change in lipid profile (TChol, LDL, HDL, C-reactive protein), Weeks -4, -1, 0, 8, 16, 24, 31, 32|Changes in adipocytokine profile (leptin, adiponectin, visfatin, and resistin), Weeks -4, -1, 0, 8, 16, 24, 31, 32|Changes in liver enzymes (ALT and AST), Weeks -4, -1, 0, 8, 16, 24, 31, 32|Edema, Weeks -4, -1, 0, 8, 16, 24, 31, 32|Change in glucose control, Weeks -1, 16, 31|Change in bone density, bone formation and resorption markers, Weeks -4, -1, 31|Change in C-Peptide, Weeks - 4, -1, 0, 1, 8, 16, 24, 31, 32|Diabetes coping behaviors and self-efficacy, Weeks -4, -1, 32|Chronic stress (as measured by questionnaire), Weeks -4 and 32|Appetite (as measured by appetite rating scale), Weeks -4, 0, 16, 32|EKG, Weeks -4, 16, 32|BNP (brain type natriuretic peptide), Weeks -4 and 32|Energy balance (physical activity recalls, food records, indirect calorimetry), Weeks -1, 16, 31|Compliance (fatty acid composition, pill counts), Weeks -1, 0, 8, 16, 24, 31, 32|Nutrition knowledge, Weeks -4, 0, 32
|
